Clinical trials: Myeloma-Multiple
Multiple Myeloma
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal doxorubicin, and dexamethasone when used…
- Trial name
- NCT01541332
- Testing
- Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma (MM)
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
- Trial name
- LINKER-MM8 (NCT07428369)
- Testing
- Linvoseltamab, Bortezomib, Lenalidomide
- Sponsor
- Regeneron Pharmaceuticals
Advanced Multiple Myeloma
A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)
The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520).
- Trial name
- NCT02092922
- Testing
- Filanesib, KSP (Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- Where
- 60 sites in United States, Belgium and 6 more
- Volunteers
- 154 people
- Sponsor
- Pfizer
Multiple Myeloma in Relapse, Multiple Myeloma
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: Does All4Cure effect patient activation as assessed by the PAM-13 survey?…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
- Trial name
- NCT05673083
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- All4Cure
Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- CERVINO (NCT06158841)
- Testing
- Etentamig, Carfilzomib, Pomalidomide
- Where
- 166 sites in United States, Australia and 23 more
- Volunteers
- 421 people
- Sponsor
- AbbVie
Multiple Myeloma, Secondary Immunodeficiency (SID)
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice.
- Trial name
- NCT05879757
- Testing
- No Intervention
- Where
- 27 sites in Argentina, Czechia and 9 more
- Volunteers
- 75 people
- Sponsor
- Takeda
Relapsed or Refractory Multiple Myeloma
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose.
- Trial name
- NCT00708292
- Testing
- AUY922, Bortezomib, Dexamethasone
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Multiple Myeloma
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab (LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT01556438
- Testing
- Tabalumab, Bortezomib IV, Bortezomib SC
- Where
- 5 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human Derived anti-BCMA CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT05302648
- Testing
- Human Derived anti-BCMA CAR-T Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma, Multiple Myeloma
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.
- Trial name
- PC002 (NCT06323447)
- Testing
- PointCheck
- Where
- 6 sites in United States, Spain
- Volunteers
- 210 people
- Sponsor
- Leuko Labs, Inc.
Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
The study will provide information on outcomes in people with multiple myeloma, or systemic AL amyloidosis, or both, under standard care. AL is short for amyloid light-chain.
- Trial name
- DOrianT (NCT04659798)
- Where
- 14 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Takeda
Multiple Myeloma
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
- Trial name
- NCT00243763
- Testing
- TKI258
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Novartis
Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
- Trial name
- ELOQUENT - 1 (NCT01335399)
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
- Where
- 235 sites in United States, Australia and 18 more
- Volunteers
- 748 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma
Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged lesion uptake of dexamethasone and therefore…
- Trial name
- AMETHYST (NCT03033316)
- Testing
- Dexamethasone
- Volunteers
- 7 people
- Sponsor
- Enceladus Pharmaceuticals BV
Multiple Myeloma
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF…
- Trial name
- NCT06514508
- Testing
- Motixafortide+G-CSF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Multiple Myeloma
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of BCMA CAR-T in the treatment of relapsed or refractory multiple myeloma
- Trial name
- NCT04447573
- Testing
- BCMA CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in…
- Trial name
- NCT04434469
- Testing
- RO7297089
- Where
- 10 sites in Australia, Belgium and 2 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.